Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado-Joseph Disease through Integration of Pathological Biomarkers and Therapeutic Strategies

• Published in: International journal of molecular sciences 2020-04, Vol.21 (9), p.3063
• Main Authors: Chen, Yu-Shuan, Hong, Zhen-Xiang, Lin, Shinn-Zong, Harn, Horng-Jyh
• Format: Article
• Language: English
• Subjects: Abnormalities; Ataxia; Autophagy; Biomarkers; Biomarkers - metabolism; Calcium influx; Clinical trials; Clinical Trials as Topic; Disease; Drug development; Drugs; FDA approval; Genetic Markers - drug effects; Glucose metabolism; Health services; Humans; Insomnia; Insulin; Insulin-like growth factors; Kinases; Machado-Joseph disease; Machado-Joseph Disease - drug therapy; Machado-Joseph Disease - genetics; Machado-Joseph Disease - metabolism; Molecular Targeted Therapy; pathological biomarkers; Patients; Phagocytosis; Review; Signal Transduction - drug effects; Signs and symptoms; spinocerebellar ataxia type 3/Machado–Joseph disease; Stem cells; Studies; Therapeutic applications; therapeutic strategies; Umbilical cord
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms21093063

Spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) is a progressive motor disease with no broadly effective treatment. However, most current therapies are based on symptoms rather than the underlying disease mechanisms. In this review, we describe potential therapeutic strategies based on known pathological biomarkers and related pathogenic processes. The three major conclusions from the current studies are summarized as follows: (i) for the drugs currently being tested in clinical trials; a weak connection was observed between drugs and SCA3/MJD biomarkers. The only two exceptions are the drugs suppressing glutamate-induced calcium influx and chemical chaperon. (ii) For most of the drugs that have been tested in animal studies, there is a direct association with pathological biomarkers. We further found that many drugs are associated with inducing autophagy, which is supported by the evidence of deficient autophagy biomarkers in SCA3/MJD, and that there may be more promising therapeutics. (iii) Some reported biomarkers lack relatively targeted drugs. Low glucose utilization, altered amino acid metabolism, and deficient insulin signaling are all implicated in SCA3/MJD, but there have been few studies on treatment strategies targeting these abnormalities. Therapeutic strategies targeting multiple pathological SCA3/MJD biomarkers may effectively block disease progression and preserve neurological function.